Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 03, 2026
Iterum Therapeutics Reports First Quarter 2021 Financial Results
07:00am, Friday, 14'th May 2021
FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021
Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021
07:30am, Friday, 07'th May 2021
DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a
Iterum Therapeutics: Delayed Review Of Its NDA For Sulopenem, But Upside Still Exists
12:06pm, Thursday, 29'th Apr 2021
Iterum Therapeutics plc is a small late-clinical-stage pharmaceutical company developing Sulopenem, their lead and sole therapeutic for urinary tract and intra-abdominal infections. Iterum has tested
Iterum: Failed Trials, Delayed NDAs, And Dilutions
06:34am, Thursday, 29'th Apr 2021
Iterum is developing sulopenem for uncomplicated urinary tract infections.
Top Biotech Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021
12:35pm, Thursday, 22'nd Apr 2021
Biotech penny stocks continue to see momentum; should you add these 3 to your watchlist? The post Top Biotech Penny Stocks to Buy?
Why Iterum (ITRM) Stock Is Plunging Today?
11:08am, Friday, 09'th Apr 2021
Iterum Therapeutics plc (NASDAQ: ITRM) shares dropped after the company in an SEC filing disclosed that the FDA needs additional time to review its sulopenem application. The application seeks a
Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
08:30am, Tuesday, 06'th Apr 2021
DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics' Science Won't Prevent Its Volatility
05:46am, Thursday, 18'th Mar 2021
Fundamentally, ITRM stock is an excellent play on multi-drug resistance pathogen solutions but you must also be aware of its extreme boom-bust cycles. The post Iterum Therapeutics' Science Won't Preve
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
07:30am, Tuesday, 16'th Mar 2021
Patrick Heron to leave the Board
ITRM Stock Price Increased 1.94% After Hours: Why It Happened
08:21am, Sunday, 14'th Mar 2021
The stock price of Iterum Therapeutics PLC (NASDAQ: ITRM) increased by 1.94% after hours on Friday. This is why it happened.
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2020 Results - Earnings Call Transcript
12:49pm, Friday, 12'th Mar 2021
Iterum Therapeutics plc (ITRM) CEO Corey Fishman on Q4 2020 Results - Earnings Call Transcript
ITRM Stock Price Increases Over 5% Pre-Market: Why It Happened
08:00am, Friday, 12'th Mar 2021
The stock price of Iterum Therapeutics PLC (NASDAQ: ITRM) has increased by over 5% pre-market. This is why it happened.
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
07:00am, Friday, 12'th Mar 2021
- -NDA for Oral Sulopenem has PDUFA date of July 25, 2021 -- - -Cash Runway into First Half of 2023 —
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
05:30pm, Friday, 05'th Mar 2021
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Unfavorable Earnings Profile Doesn't Bode Well for Iterum Therapeutics Stock
12:01pm, Tuesday, 02'nd Mar 2021
It's encouraging that Iterum's oral antibiotic has blockbuster status potential, but the basic earnings data on ITRM stock signal caution. The post Unfavorable Earnings Profile Doesn't Bode Well for I
